Summary of key recommendations: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 8: Line 8:
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
|-
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' RECOMMENDATION 1 HERE''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki>
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.'''Clinical ASCVD
*Age 75 y and no safety concerns: High-intensity statin
*Age >75 y or safety concerns: Moderate-intensity statin''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' RECOMMENDATION 2 HERE''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.'''Primary prevention – Primary LDL-C ‡190 mg/dL
*Rule out secondary causes of hyperlipidemia
*Age !21 y: High-intensity statin''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.'''Primary preventiondDiabetes 40–75 years of age and LDL-C 70–189 mg/dL
*Moderate-intensity statin''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki>
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''4.'''  Primary prevention – No diabetes 40–75 years of age and LDL-C 70–189 mg/dL
*Estimate 10-y ASCVD risk using the Risk Calculator based on the Pooled Cohort Equationsy in those NOT receiving a statin; estimate risk every 4–6 y''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|-
|}
|}


Revision as of 17:42, 27 October 2016

Template:Hypercholesterolemia Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Summary of Key Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults

Class I
"1.Clinical ASCVD
  • Age 75 y and no safety concerns: High-intensity statin
  • Age >75 y or safety concerns: Moderate-intensity statin(Level of Evidence: A)"
"2.Primary prevention – Primary LDL-C ‡190 mg/dL
"3.Primary preventiondDiabetes 40–75 years of age and LDL-C 70–189 mg/dL
"4. Primary prevention – No diabetes 40–75 years of age and LDL-C 70–189 mg/dL
  • Estimate 10-y ASCVD risk using the Risk Calculator based on the Pooled Cohort Equationsy in those NOT receiving a statin; estimate risk every 4–6 y(Level of Evidence: B)"
Class III (Harm)
"1. RECOMMENDATION 1 HERE (Level of Evidence: C)"
"2. RECOMMENDATION 2 HERE (Level of Evidence: C)"
Class III (No Benefit)
"1. RECOMMENDATION 1 HERE (Level of Evidence: C)"
"2. RECOMMENDATION 2 HERE (Level of Evidence: C)"
Class IIa
"1. RECOMMENDATION 1 HERE (Level of Evidence: C)"
"2. RECOMMENDATION 2 HERE (Level of Evidence: C)"
Class IIb
"1. RECOMMENDATION 1 HERE (Level of Evidence: C)"
"2. RECOMMENDATION 2 HERE (Level of Evidence: C)"

References


Template:WikiDoc Sources CME Category::Cardiology

Retrieved from "https://www.wikidoc.org/index.php?title=Summary_of_key_recommendations&oldid=1264382"